VivoSeq
Metabolic & Endocrine

Severe Hypertriglyceridemia

3

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Severe Hypertriglyceridemia is an early-stage landscape with 3 programs across 4 companies. The most active players are Zhejiang Doer Biologics Co., Ltd., Arrowhead Pharmaceuticals, 89bio. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zhejiang Doer Biologics Co., Ltd.

4 programs

Phase 3Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

1 program

Phase 389bio logo

89bio

1 program

Phase 3Eli Lilly logo

Eli Lilly

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Solbinsiran

Eli Lilly

Phase 32

Plozasiran

Arrowhead Pharmaceuticals

Pegozafermin

89bio

Approved
No programs

Analysis

Modality Breakdown

4programs
RNA therapy250%
Small molecule125%
Protein / enzyme125%

Modality classified for 50% of 8 pipeline programs.

Analysis

Trial Status

5

clinical trials

Not yet recruiting2 · 40%
Recruiting2 · 40%
Completed1 · 20%

Clinical Trials

Trial Activity

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of DR10624 in Subjects With Severe Hypertriglyceridemia Receiving Stable Lipid-Modifying Therapy
Not yet recruiting·ZZhejiang Doer Biologics Co., Ltd.·Phase 3·NCT07693777·480 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07269210·60 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
Completed·89bio logo89bio·Phase 3·NCT05852431·369 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia
Not yet recruiting·ZZhejiang Doer Biologics Co., Ltd.·Phase 3·NCT07680829·378 enrolled
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT06880770·288 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)